CR10802A - COMPUESTOS TETRAHIDROCICLOPENTA[b]INDOL COMO MODULARES DEL RECEPTOR ANDROGENO - Google Patents

COMPUESTOS TETRAHIDROCICLOPENTA[b]INDOL COMO MODULARES DEL RECEPTOR ANDROGENO

Info

Publication number
CR10802A
CR10802A CR10802A CR10802A CR10802A CR 10802 A CR10802 A CR 10802A CR 10802 A CR10802 A CR 10802A CR 10802 A CR10802 A CR 10802A CR 10802 A CR10802 A CR 10802A
Authority
CR
Costa Rica
Prior art keywords
tetrahydrociclopenta
indol
modular
compounds
androgen receptor
Prior art date
Application number
CR10802A
Other languages
English (en)
Inventor
Gavardinas Konstantinos
Edward Green Jonathan
Kondaji Jadhav Prabhakar
Paul Matthews Donald
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR10802A publication Critical patent/CR10802A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invencion proporciona un compuesto de la Formula (I) o una sal farmaceuticamente aceptable del mismo; composiciones farmaceuticas que comprenden un compuesto de la Formula (I) en combinacion con un portador, diluyente, o excipiente adecuado; y metodos para tratar trastornos fisiologicos, particularmente reducir la masa en los huesos, osteoporosis, osteopenia, o reduccion de masa o fuerza muscular, que comprende administrar un compuesto de la Formula (I), o una sal farmaceuticamente aceptable del mismo.
CR10802A 2006-11-20 2009-05-19 COMPUESTOS TETRAHIDROCICLOPENTA[b]INDOL COMO MODULARES DEL RECEPTOR ANDROGENO CR10802A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20

Publications (1)

Publication Number Publication Date
CR10802A true CR10802A (es) 2009-07-13

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10802A CR10802A (es) 2006-11-20 2009-05-19 COMPUESTOS TETRAHIDROCICLOPENTA[b]INDOL COMO MODULARES DEL RECEPTOR ANDROGENO

Country Status (37)

Country Link
US (1) US7968587B2 (es)
EP (1) EP2094658B1 (es)
JP (1) JP5399259B2 (es)
KR (1) KR101121471B1 (es)
CN (1) CN101541749B (es)
AR (1) AR063559A1 (es)
AT (1) ATE538091T1 (es)
AU (1) AU2007324046B2 (es)
BR (1) BRPI0719092B8 (es)
CA (1) CA2670340C (es)
CL (1) CL2007003182A1 (es)
CO (1) CO6190513A2 (es)
CR (1) CR10802A (es)
CY (1) CY1112284T1 (es)
DK (1) DK2094658T3 (es)
EA (1) EA015627B1 (es)
EC (1) ECSP099350A (es)
ES (1) ES2376048T3 (es)
HK (1) HK1134089A1 (es)
HR (1) HRP20120032T1 (es)
IL (1) IL198410A (es)
JO (1) JO2800B1 (es)
MA (1) MA31072B1 (es)
MX (1) MX2009005251A (es)
MY (1) MY154547A (es)
NO (1) NO342531B1 (es)
NZ (1) NZ576296A (es)
PE (1) PE20081161A1 (es)
PL (1) PL2094658T3 (es)
PT (1) PT2094658E (es)
RS (1) RS52191B (es)
SI (1) SI2094658T1 (es)
TN (1) TN2009000189A1 (es)
TW (1) TWI398438B (es)
UA (1) UA98777C2 (es)
WO (1) WO2008063867A2 (es)
ZA (1) ZA200903096B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716320C (en) 2008-02-22 2014-01-28 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
DK2297100T3 (da) * 2008-05-16 2012-12-17 Lilly Co Eli Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
BR112013007685B1 (pt) 2010-09-28 2021-11-09 Radius Pharmaceuticals, Inc Compostos moduladores de receptor andrógeno seletivos, composição farmacêutica compreendendo os referidos compostos, método de identificação de um composto capaz de modular um receptor andrógeno, usos de um composto ou da composição e processo para a preparação de um composto
BR112013028895A2 (pt) 2011-05-10 2016-08-09 Bayer Ip Gmbh (tio)carbonilamidinas bicíclicas
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
DK3122426T3 (da) 2014-03-28 2023-04-03 Univ Duke Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
AU2017281038B2 (en) 2016-06-22 2021-09-09 Ellipses Pharma Ltd AR+ breast cancer treatment methods
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
KR20230109795A (ko) 2017-01-05 2023-07-20 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
JP2023511612A (ja) * 2020-01-27 2023-03-20 エイルゲン ファーマ リミテッド 腎臓疾患の治療のためのテトラヒドロシクロペンタ［ｂ］インドール化合物
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) * 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) * 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) * 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
CA2387201C (en) * 1999-10-14 2009-05-26 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
EP1423366A1 (en) 2001-08-09 2004-06-02 Eli Lilly And Company Cyclopenta b ! indole derivatives as spla2 inhibitors
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
JP4484108B2 (ja) * 2002-05-16 2010-06-16 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗作用を有する化合物
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
CA2557745A1 (en) * 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
EP1817026A2 (en) * 2004-11-22 2007-08-15 SmithKline Beecham Corporation Hcv inhibitors
EP1817025A2 (en) 2004-11-23 2007-08-15 PTC Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
AU2006214233A1 (en) 2005-02-17 2006-08-24 Wyeth Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
JP5204650B2 (ja) 2005-06-24 2013-06-05 イーライ リリー アンド カンパニー アンドロゲン受容体調節物質として有用なテトラヒドロカルバゾール誘導体
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
DK2297100T3 (da) 2008-05-16 2012-12-17 Lilly Co Eli Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer

Also Published As

Publication number Publication date
AU2007324046B2 (en) 2012-04-05
MA31072B1 (fr) 2010-01-04
US7968587B2 (en) 2011-06-28
KR20090082229A (ko) 2009-07-29
WO2008063867A2 (en) 2008-05-29
ES2376048T3 (es) 2012-03-08
PE20081161A1 (es) 2008-08-15
WO2008063867A3 (en) 2008-07-31
CA2670340C (en) 2014-05-20
PT2094658E (pt) 2012-02-22
MX2009005251A (es) 2009-08-19
HRP20120032T1 (hr) 2012-02-29
ECSP099350A (es) 2009-06-30
CN101541749B (zh) 2013-03-27
JO2800B1 (en) 2014-03-15
BRPI0719092B1 (pt) 2020-08-18
IL198410A (en) 2013-09-30
US20100069404A1 (en) 2010-03-18
NZ576296A (en) 2011-11-25
CY1112284T1 (el) 2015-12-09
EP2094658A2 (en) 2009-09-02
BRPI0719092A2 (pt) 2013-12-03
TN2009000189A1 (en) 2010-10-18
EA015627B1 (ru) 2011-10-31
IL198410A0 (en) 2010-02-17
TW200827347A (en) 2008-07-01
TWI398438B (zh) 2013-06-11
KR101121471B1 (ko) 2012-02-28
ATE538091T1 (de) 2012-01-15
JP5399259B2 (ja) 2014-01-29
NO342531B1 (no) 2018-06-11
CN101541749A (zh) 2009-09-23
AR063559A1 (es) 2009-02-04
CL2007003182A1 (es) 2008-06-27
MY154547A (en) 2015-06-30
BRPI0719092B8 (pt) 2021-05-25
DK2094658T3 (da) 2012-02-13
RS52191B (en) 2012-10-31
JP2010510231A (ja) 2010-04-02
SI2094658T1 (sl) 2012-04-30
EP2094658B1 (en) 2011-12-21
NO20092103L (no) 2009-05-28
UA98777C2 (en) 2012-06-25
ZA200903096B (en) 2010-07-28
CA2670340A1 (en) 2008-05-29
PL2094658T3 (pl) 2012-05-31
CO6190513A2 (es) 2010-08-19
EA200970500A1 (ru) 2009-10-30
HK1134089A1 (en) 2010-04-16
AU2007324046A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
CR10802A (es) COMPUESTOS TETRAHIDROCICLOPENTA[b]INDOL COMO MODULARES DEL RECEPTOR ANDROGENO
ATE457979T1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
PL1891038T3 (pl) Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego
EA201071317A1 (ru) ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
MX2009013989A (es) Terapia en combinacion para depresion.
CO6270360A2 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
UY30460A1 (es) Compuestos terapéuticos
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
GB0722077D0 (en) Compounds
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
MX2012007217A (es) Derivados de (metilsulfonil) etilbenceno isoindolina y sus usos terapeuticos.
MX2007005525A (es) Tratamiento terapeutico de resorcion ose acelerada.
WO2008004100A9 (en) Therapeutic compounds
DOP2009000117A (es) Compuestos de tetrahidrociclopenta[b]indol como moduladores del receptor de andrógenos
TR201901677T4 (tr) Sitidin analoglarının oral formülasyonları ve bunların kullanım yöntemleri.